Dose Escalation of Luspatercept on Trial and Real-World Data
Guillermo Garcia-Manero, MD, addresses clinical research investigating luspatercept dose titration practices in patients with lower-risk MDS.
Video content above is prompted by the following:
- Per the COMMANDS trial schema, luspatercept was initiated at 1.0 mg/kg with titration allowed at 2 levels to a maximum of 1.75 mg/kg.
- Please discuss the efficacy data associated with up titration and the number of participants who required dose escalation in the trial.
- At the 2024 EHA Congress, data was presented on real-world dose escalation of luspatercept and clinical outcomes. Please discuss the findings and the impact on TI for patients originally TD and for patients for patients NTD prior to dose escalation.
Recent Videos
Related Content
